Elamipretide is a synthetic mitochondria-targeted tetrapeptide developed to interact with cardiolipin, a phospholipid located in the inner mitochondrial membrane. It is designed to target mitochondrial dysfunction and has been investigated in several disorders involving impaired mitochondrial function.
Elamipretide is also known by the development codes MTP-131 and Bendavia. It is a short, positively charged peptide composed of four amino acids and has been investigated for its potential effects on mitochondrial structure and function.
The compound selectively associates with cardiolipin in the inner mitochondrial membrane. This interaction has been investigated for its potential to stabilize mitochondrial membrane structure, support electron transport chain function and reduce mitochondrial oxidative stress.
Elamipretide is a peptide-based pharmaceutical compound intended for pharmaceutical research and development. Unlike conventional small-molecule APIs, peptide quality assessment can involve specialized analytical characterization, including peptide identity, purity, related peptides, aggregation and other product-specific quality attributes.
Elamipretide has been investigated in mitochondrial diseases and other conditions associated with mitochondrial dysfunction. Its development has included research in Barth syndrome, mitochondrial myopathy and other mitochondrial disorders.
Elamipretide is designed to selectively interact with cardiolipin, an important phospholipid in the inner mitochondrial membrane. Cardiolipin is involved in the organization and function of mitochondrial respiratory-chain complexes.
By associating with cardiolipin, elamipretide has been investigated for its potential to improve mitochondrial membrane organization, support oxidative phosphorylation and reduce oxidative damage.
Elamipretide has been investigated in areas involving mitochondrial dysfunction, including:
Its clinical development has included investigation of mitochondrial function, exercise capacity and disease-related outcomes.
As a peptide-based pharmaceutical compound, Elamipretide should be manufactured and tested according to the applicable approved specification and appropriate pharmaceutical quality standards.
Relevant quality attributes may include:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |